<DOC>
	<DOCNO>NCT00949988</DOCNO>
	<brief_summary>This open-label phase I/II study investigate combination dasatinib rituximab therapy patient relapsed/refractory CLL . In phase I , eligible subject take either 100 mg 140 mg dasatinib daily along rituximab day 1 cycle 6 cycle . In phase II , eligible subject receive dose dasatinib , establish phase I portion , along rituximab day 1 cycle 6 cycle . The investigator hypothesize combination dasatinib rituximab demonstrate efficacy treatment patient relapsed/refractory CLL .</brief_summary>
	<brief_title>A Study Dasatinib Rituximab Relapsed/Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>In phase I , patient enrol standard `` 3+3 '' dose escalation scheme two dasatinib cohort dose 100 mg QD 140 mg QD x 28 days/cycle rituximab 500 mg/m2 day 1 cycle ( 375 mg/m2 day 1 cycle 1 ) . During first cycle dose cohort patient receive dasatinib day -7 0 allow pharmacokinetic pharmacodynamic analysis single agent dasatinib dose . Cohorts assess DLTs first 2 cycle . Treatment continue 6 cycle intolerable toxicity disease progression . It estimate accrual 3-6 patient complete 4-6 month depend DLTs observe . The dasatinib dose establish phase I move forward phase II setting . If DLTs , phase II dose chosen base PD parameter . Dasatinib administer 28 days/cycle rituximab 500 mg/m2 day 1 cycle ( 375 mg/m2 day 1 cycle 1 ) 6 cycle intolerable toxicity disease progression . For portion study , additional 22 patient enrolled 6-month period total 28 patient choose dose level . For , phase I II , patient complete six cycle D+R therapy endpoint evaluate 8 week treatment . Patients follow disease progression , study withdrawal death . Patients PR CR eligible remain dasatinib alone .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Confirmed immunohistological diagnosis Bcell CLL Rai Stage III IV disease , stage 0II disease meet NCIWG criterion active disease indicate one follow diseaserelated symptom : Weight loss ≥ 10 % within previous 6 month Extreme fatigue Fever great 100.5 degree Fahrenheit ≥ 2 week without evidence infection Night sweat without evidence infection Evidence progressive marrow failure base development worsen anemia ( &lt; 10 g/dL ) thrombocytopenia ( &lt; 100,000 cells/mL ) Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid therapy Massive ( &gt; 6 cm leave costal margin ) progressive splenomegaly Bulky ( &gt; 10 cm cluster ) progressive lymphadenopathy Progressive lymphocytosis &gt; 50 % increase 2month period , anticipate double time &lt; 6 month 2 . Relapsed/ Refractory CLL progress ≥1 prior treatment include purine nucleoside analogcontaining regimen , alkylating agent , antibody ( rituximab alemtuzumab ) intolerance purine nucleoside analogcontaining therapy unwilling receive chemotherapy treatment . 3 . Age 18 old 4 . ECOG Performance Status 02 ( Appendix B ) 5 . Adequate organ function : Serum creatinine &lt; 2x institutional upper limit normal ( ULN ) Total bilirubin &lt; 2x institutional ULN AST , ALT &lt; 2.5x institutional ULN Serum sodium , potassium , magnesium , phosphate calcium &gt; institutional low limit normal ( LLN ) 6 . Ability take oral medication ( dasatinib must swallow whole ) 7 . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( sensitivity ≤ 25 IU/L HCG ) within 72 hrs prior start study drug administration 8 . Persons reproductive potential must agree use adequate method contraception throughout treatment least 4 week study drug stop 9 . Ability understand willingness sign write informed consent document EXCLUSION CRITERIA : 1 . No prior CLLrelated treatment within 28 day start treatment dasatinib . 2 . No concurrent use investigation agent . 3 . Concurrent medical condition may increase risk toxicity , include : Uncontrolled significant cardiovascular disease , include : Myocardial infarction , congestive heart failure uncontrolled angina within 6 month Diagnosed congenital long QT syndrome Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsade de Pointes ) Prolonged QTcF interval preentry ECG ( &gt; 450 msec ) 2nd/3rd degree heart block , uncontrolled hypertension heart rate &lt; 50 History significant bleeding disorder unrelated CLL , include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Ongoing recent significant GI bleeding within 3 month Hypokalemia hypomagnesemia correct Pleural pericardial effusion grade Past current malignancy , except : Cervical carcinoma Stage 1B less Noninvasive basal cell squamous cell skin carcinoma Malignant melanoma complete response duration &gt; 10 year Other cancer diagnose complete response duration &gt; 5 year Major systemic illness include active infection active secondary malignancy would , opinion Investigator , interfere patient 's ability comply protocol , compromise patient safety , interfere interpretation study result 4 . No history allergic reaction dasatinib . 5 . Use Prohibited Concomitant Medications Subjects require follow prohibited therapy enrol : Bisphosphonates Intravenous bisphosphonates withhold first 8 week treatment due risk hypocalcemia . After need Ca2+ supplementation assess level document &gt; LLN , subject prior bisphosphonate may restart caution Investigator 's discretion . CYP3A4 Inhibitors/Inducers/Substrates Dasatinib primarily metabolize CYP3A4 enzyme . Therefore , potent inhibitor CYP3A4 prohibit study ; medication , washout period ≥ 7 day require prior start dasatinib . Subjects advise consume substantial quantity grapefruit juice . Drugs may increase dasatinib plasma concentration : CYP3A4 Inhibitors : Dasatinib CYP3A4 substrate . Concomitant use dasatinib drug inhibit CYP3A4 ( e.g. , ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure dasatinib avoid . In patient receive treatment dasatinib , close monitoring toxicity dasatinib dose reduction consider systemic administration potent CYP3A4 inhibitor avoid . Drugs may decrease dasatinib plasma concentration : CYP3A4 Inducers : Drugs induce CYP3A4 activity may decrease dasatinib plasma concentration . In patient CYP3A4 inducer ( eg , dexamethasone , phenytoin , carbamazepine , rifampicin , phenobarbital ) indicate , alternative agent less enzyme induction potential use . If dasatinib must administer CYP3A4 inducer , dose increase dasatinib consider approve principal investigator . Drugs may plasma concentration alter dasatinib : CYP3A4 Substrates : CYP3A4 substrates know narrow therapeutic index alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , ergot alkaloid ( ergotamine , dihydroergotamine ) administer caution patient receive dasatinib . Lesspotent inhibitor , inducer , substrate CYP3A4 restrict . St. John 's Wort ( Hypericum perforatum ) : May decrease dasatinib plasma concentration unpredictably . Patients receive dasatinib take St. John 's wort . Antacids Nonclinical data demonstrate solubility dasatinib pH dependent . Simultaneous administration dasatinib antacid avoid . If antacid therapy need , antacid dose administer least 2 hour prior 2 hour dose dasatinib . H2 Blockers/Proton Pump Inhibitors Longterm suppression gastric acid secretion H2 blocker proton pump inhibitor ( eg , famotidine omeprazole ) likely reduce dasatinib exposure . The concomitant use H2 blocker proton pump inhibitor dasatinib recommend . The use antacid consider place H2 blocker proton pump inhibitor patient receive dasatinib therapy . Medications prolong QT Interval Subjects enrol study take begin take concomitant medication know prolong QT interval . If medication already take patient study start , washout period ≥ 7days require prior start dasatinib . Medications know prolong QT interval and/or generally accept risk cause Torsades de Pointes ventricular arrhythmia ( see http : //www.qtdrugs.org/medicalpros/druglists/druglists.htm ) : Quinidine , procainamide , disopyramide Amiodarone , sotalol , ibutilide , dofetilide Erythromycin , clarithromycin Chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide Cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine Should Investigator believe begin therapy potentially QT prolong medication ( one explicitly prohibit ) vital individual subject 's care , Investigator must check subject 's prior ontherapy ECG show QTcF ≥ 450 msec increase QTc ≥ 60 msec baseline value . Anticoagulants Medications inhibit Platelet Function Caution exercise patient require take medication inhibit platelet function anticoagulant . Subjects enrol study take concomitant medication durably inhibit platelet function . For medication , washout period ≥ 7days require prior start dasatinib . ( Agents inhibit platelet function transiently inhibit coagulation mechanism restrict . ) Medications directly durably inhibit platelet function include : aspirin aspirincontaining combination , clopidogrel , dipyridamole tirofiban , dipyridamole , epoprostenol , eptifibatide , cilostazol , abciximab , ticlopidine , cilostazol Medications directly durably inhibit anticoagulation include : warfarin , heparin/low molecular weight heparin [ e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ] Exceptions : lowdose warfarin prophylaxis prevent catheter thrombosis , heparin flush IV line . 6 . Women pregnant ( include positive pregnancy test ) breastfeeding , unable/unwilling practice acceptable method avoid pregnancy entire study period least 4 week cessation study drug , men sexual partner thereof . Sexually active woman childbearing potential ( WOCBP ) must use effective method birth control course study , manner risk failure minimize . Prior study enrollment , WOCBP must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . All WOCBP MUST negative pregnancy test prior first receive dasatinib . If pregnancy test positive , patient must receive dasatinib must enrol study . 7 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>